Pentoxifylline improves the flow property of blood. It is known to enhance tissue oxygenation. It produces dose-related decrease in blood viscosity. It also inhibits neutrophil adhesion and activation.
Pharmacokinetics: Pentoxifylline is readily absorbed through the gastrointestinal route but undergoes first-pass hepatic metabolism. Some metabolites are active. The apparent plasma t½ of pentoxifylline is reported to be 0.4-0.8 hr; that of the metabolites varies from 1-1.6 hrs. In 24 hrs, most of the dose is excreted in the urine mainly as metabolites and <4½ is recovered as unchanged drug in the feces. Elimination of pentoxifylline is decreased in elderly patients and patients with hepatic disease.
As a vasodilator in the treatment of peripheral and vascular disorders.
1 tablet taken 3 times daily with meals. To be taken with some liquid or as prescribed by the physician.
Overdosage with pentoxifylline may be associated with fever, flushing, faintness, hypotension, drowsiness, agitation and seizures.
Patients with recent retinal or cerebral hemorrhage.
Gastrointestinal complaints, cardiac arrhythmias, angina pectoris, flushing. Bleeding events have been reported rarely, usually in association with bleeding risk factors, dizziness and headache.
Concomitant administration of warfarin may prolong prothrombin time. Concomitant theophylline and hypertensive therapy may potentiate their action, requiring dosage adjustment.
Store at a temperature not exceeding 30°C.
Shelf-Life: 24 months.
C04AD03 - pentoxifylline ; Belongs to the class of purine derivative agents. Used as peripheral vasodilators.
Tab 400 mg (extended-release) x 100's.